Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $106.4 million.

  • Akebia Therapeutics' Accumulated Expenses rose 10381.12% to $106.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $106.4 million, marking a year-over-year increase of 10381.12%. This contributed to the annual value of $63.5 million for FY2024, which is 631.14% down from last year.
  • Akebia Therapeutics' Accumulated Expenses amounted to $106.4 million in Q3 2025, which was up 10381.12% from $91.6 million recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Accumulated Expenses ranged from a high of $144.7 million in Q3 2021 and a low of $51.1 million during Q1 2023
  • Moreover, its 5-year median value for Accumulated Expenses was $75.8 million (2022), whereas its average is $84.1 million.
  • Per our database at Business Quant, Akebia Therapeutics' Accumulated Expenses crashed by 5528.92% in 2023 and then surged by 10381.12% in 2025.
  • Quarter analysis of 5 years shows Akebia Therapeutics' Accumulated Expenses stood at $109.0 million in 2021, then plummeted by 30.49% to $75.8 million in 2022, then decreased by 10.61% to $67.7 million in 2023, then fell by 6.31% to $63.5 million in 2024, then skyrocketed by 67.7% to $106.4 million in 2025.
  • Its last three reported values are $106.4 million in Q3 2025, $91.6 million for Q2 2025, and $71.3 million during Q1 2025.